Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

Summary

The purpose of this study is to determine if the combination of therapy to strengthen the immune system (Interleukin - 2) plus a specific tumor target therapy (Bevacizumab) can prolong the time between the start of treatment and disease progression, decrease tumor size, as well as determine if the combination therapy is safer and less toxic than the standard treatment for renal cell carcinoma.

Timeline

Start

2006-10

Primary completion

2007-10

Completion

2007-11

Outcome

Outcome not reported

Stopped: “contract issues”

Drugs

Indications